Alterity Therapeutics (PRNAF) Price & Analysis

7 Followers

PRNAF Stock Chart & Stats

$0.40

-$0.10(-22.22%)

At close: Jul 27 4:00 PM EDT

$0.40

-$0.10(-22.22%)

Day’s Range― - ―

52-Week Range$0.06 - $0.55

Previous CloseN/A

Volume3.16K

Average Volume (3M)83.00

Market Cap

$56.07M

Enterprise Value$32.34M

Total Cash (Recent Filing)$37.32M

Total Debt (Recent Filing)$193.47K

Price to Earnings (P/E)―

Beta2.86

Next Earnings

Mar 04, 2027

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding229,150,850

10 Day Avg. Volume250

30 Day Avg. Volume83

Financial Highlights & Ratios

PEG Ratio-0.33

Price to Book (P/B)2.83

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-279.87

Enterprise Value/Ebitda-1.14

Forecast

1Y Price Target

$0.66

Price Target Upside65.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)$1.28M

Bulls Say, Bears Say

Bulls Say

Low LeverageExtremely low leverage reduces financial risk and preserves flexibility while Alterity funds development. A less debt-dependent capital structure can help management direct available resources toward clinical programs and absorb operating losses without the added burden of substantial interest or refinancing obligations.

Neurodegenerative Disease FocusA focused pipeline addressing underlying pathology gives Alterity a clearly defined scientific and commercial objective rather than a broad, unfocused discovery strategy. Success in these indications could support meaningful differentiation because the programs are intended to modify disease, not only manage symptoms.

Multiple Monetization RoutesThe proprietary-asset model offers more than one eventual route to economic value: partnering or licensing could provide external development support, while approval could enable direct commercialization. These pathways create strategic flexibility, although each depends on successful clinical and regulatory progress.

Bears Say

No Current Product RevenueZero recent revenue confirms that Alterity has not yet established a commercial earnings base. Until a candidate is approved and monetized, the company remains dependent on development progress and external funding, leaving future operating performance highly contingent on clinical and regulatory outcomes.

Persistent Operating LossesRecurring operating and net losses show that the business is still in a cash-consuming development phase rather than scaling a profitable platform. Continued losses can erode equity over time and make the company’s long-term financial profile dependent on achieving a commercial inflection or securing additional capital.

Negative Cash GenerationPersistent negative operating and free cash flow means Alterity is not currently self-funding its research and operations. Ongoing dependence on external capital can constrain development plans and increase financing requirements until the company generates product revenue, licensing proceeds, or another durable source of cash.

Alterity Therapeutics News

Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data

Alterity announced additional analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy were...

10d ago

ATHE

Alterity Therapeutics management to meet virtually with Lake Street

Virtual Meeting to be held on September 21 at 11:30 am hosted by Lake Street. Published first on...

30d ago

ATHE

Alterity Therapeutics management to meet virtually with Lake Street

Virtual Meeting to be held on September 17 at 11 am hosted by Lake Street. Published first on...

30d ago

ATHE

Alterity Therapeutics initiated with a Buy at Lake Street

Lake Street analyst Thomas Flaten initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price...

30d ago

ATHE

Alterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference

Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics will participate in the Canaccord Genuity Drug...

6d ago

Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported new analyses from its...

10d ago

Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has scheduled its next Annual...

20d ago

Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an announcement. Alterity Therapeutics has issued a corporate presentation outlining the...

22d ago

Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics, a clinical-stage biotechnology company, develops disease-modifying therapies...

27d ago

Alterity Therapeutics Seeks Quotation for New ASX Shares

Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics has applied for quotation of 50,000 new...

29d ago

Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics Limited, an ASX-listed Australian biopharmaceutical company, has...

1M ago

Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares

Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics Limited has applied for quotation of 8,400,000...

1M ago

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modifying treatments...

1M ago

Alterity Therapeutics Updates Director Equity Holdings After Option Expiry

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has reported a change in the securities...

1M ago

PRNAF FAQ

What was Alterity Therapeutics’s price range in the past 12 months?

Alterity Therapeutics lowest stock price was $0.06 and its highest was $0.55 in the past 12 months.

What is Alterity Therapeutics’s market cap?

Alterity Therapeutics’s market cap is $56.07M.

When is Alterity Therapeutics’s upcoming earnings report date?

Alterity Therapeutics’s upcoming earnings report date is Mar 04, 2027 which is in 140 days.

How were Alterity Therapeutics’s earnings last quarter?

Alterity Therapeutics released its earnings results on Feb 25, 2026. The company reported -$0.031 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.011.

Is Alterity Therapeutics overvalued?

According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics pay dividends?

Alterity Therapeutics does not currently pay dividends.

What is Alterity Therapeutics’s EPS estimate?

Alterity Therapeutics’s EPS estimate is >-0.01.

How many shares outstanding does Alterity Therapeutics have?

Alterity Therapeutics has 229,150,850 shares outstanding.

What happened to Alterity Therapeutics’s price movement after its last earnings report?

Alterity Therapeutics reported an EPS of -$0.031 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Alterity Therapeutics?

Currently, no hedge funds are holding shares in PRNAF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-48.25%

Trailing 12-Months

Asset Growth

5.70%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Alterity Therapeutics

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

Alterity Therapeutics (PRNAF) Earnings & Revenues

Historic Earnings Reports

PRNAF Stock 12 Month Forecast

Average Price Target

$0.66

▲(65.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.66347715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.66347715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.66347715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4202674730769231,0.44053494615384614,0.46080241923076926,0.4810698923076923,0.5013373653846154,0.5216048384615385,0.5418723115384616,0.5621397846153846,0.5824072576923076,0.6026747307692307,0.6229422038461538,0.6432096769230768,{"y":0.66347715,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4202674730769231,0.44053494615384614,0.46080241923076926,0.4810698923076923,0.5013373653846154,0.5216048384615385,0.5418723115384616,0.5621397846153846,0.5824072576923076,0.6026747307692307,0.6229422038461538,0.6432096769230768,{"y":0.66347715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4202674730769231,0.44053494615384614,0.46080241923076926,0.4810698923076923,0.5013373653846154,0.5216048384615385,0.5418723115384616,0.5621397846153846,0.5824072576923076,0.6026747307692307,0.6229422038461538,0.6432096769230768,{"y":0.66347715,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.54,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.505,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.505,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.055,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.055,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.055,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >